Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 50Vincristine 49Doxorubicin 44Prednisone 42Rituximab 32Radiotherapy 27Etoposide 27Methotrexate 24Filgrastim 24Cytarabine 23Dexamethasone 15Granulocyte Colony-Stimulating Factor 13Bleomycin 13Vinblastine 12Peripheral Blood Stem Cell Transplantation 12Leucovorin 11Gene Expression Profiling 10Bortezomib 10Immunohistochemistry 9Procarbazine 8Polymerase Chain Reaction 8Gemcitabine 8Melphalan 7Amplified Fragment Length Polymorphism Analysis 7VAP-cyclo protocol 6Mercaptopurine 6Ifosfamide 6Dacarbazine 6Carmustine 6Microarray Analysis 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma × pevonedistat × Clear all
NCT03323034 2024-10-22

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Children's Oncology Group

Phase 1 Completed
30 enrolled 19 charts
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡